What changed for Pulmonary Hypertension
A plain English summary of what recently moved in the public data Voxsanity tracks for Pulmonary Hypertension. Updated from government registries. Not medical advice.
How to read these changes: every figure on this page is the difference between two snapshots of what Voxsanity had tracked on each date. Voxsanity only began taking daily snapshots in July 2026 and is still ingesting the public registries, so a rise here is mostly our own coverage expanding rather than new research appearing. Read it as our tracked coverage growing, not as a claim about real-world research changing this fast: it overstates how much actually changed.
Comparing the two most recent snapshots, 27 July 2026 and 28 July 2026.
- Trials recruiting at Australian sites 7 to 8 (+1)
- Trials recruiting worldwide 226 to 229 (+3)
- Trials on record 1,634 to 1,630 (-4)
Newly subsidised on the PBS
No medicines were newly subsidised on the PBS for Pulmonary Hypertension in July 2026. Voxsanity tracks 10 PBS-subsidised medicines for this condition; none of them was listed for the first time this month.
Source: Pharmaceutical Benefits Scheme (PBS), © Commonwealth of Australia. Data used and redistributed under permission; not modified from its original wording where displayed verbatim.
Past updates
Tracking began in July 2026. Month on month changes will appear here once a second month of data has been recorded. Until then, the comparison above shows the most recent movement.
Recent trend
Weekly, most recent weeks (fills out to a monthly trend as history grows).
Recent trial results
The 30 most recent of 133 trials tracked for Pulmonary Hypertension that have reported results to a public registry.
AI generated results summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
-
NCT04175600 · results posted 20 July 2026
According to the results reported on ClinicalTrials.gov, this trial (NCT04175600) enrolled 138 people with pulmonary arterial hypertension (a condition where blood pressure in the arteries supplying the lungs is abnormally high) — 69 received a placebo (dummy treatment) and 69 received a medicine called selexipag. The trial was primarily measuring how long it took for participants' condition to get worse, defined by specific events such as death, being added to a lung transplant waiting list, being hospitalised due to worsening disease, or other signs of clinical decline. The reported data sh...
Read the full trial page · View reported results on ClinicalTrials.gov ↗
-
NCT04084678 · results posted 6 July 2026
According to the results reported on ClinicalTrials.gov, this trial (NCT04084678) enrolled 10 participants in total — 8 received ralinepag and 2 received a placebo (a dummy treatment with no active ingredient). The trial was measuring a specific aspect of exercise capacity called "peak VO2," which is the maximum amount of oxygen the body can use during intense exercise, tested using a specialised exercise test (called a CPET, or cardiopulmonary exercise test). This measurement was taken at the start of the trial and again after 28 weeks to see how it changed. The reported data shows that, on...
-
NCT05975905 · results posted 2 July 2026
According to the results reported on ClinicalTrials.gov, this trial tested an investigational treatment called KER-012 in people with pulmonary arterial hypertension (a condition where the blood pressure inside the lungs is abnormally high). Participants were already receiving standard background treatment for the condition. A total of 113 people took part across four groups — 24 in Arm 1 (placebo), 25 in Arm 2, 25 in Arm 3, and 39 in Arm 4 — over a 24-week treatment period, with a further extension phase planned. The trial was primarily looking at changes in pulmonary vascular resistance (a m...
-
NCT04266197 · results posted 17 June 2026
According to the results reported on ClinicalTrials.gov, this trial tested an investigational drug called RT234 across 42 participants in total, split into three groups based on dose level: 7 people received the 0.5 mg dose, 21 received the 1.0 mg dose, and 14 received the 2.0 mg dose. All 42 participants completed the study. The trial was measuring how RT234 might affect the body's ability to use oxygen during exercise, as well as how efficiently the lungs work, and how much breathlessness and physical effort participants reported during a supervised exercise test (called a cardiopulmonary ex...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT04811092 · results posted 27 April 2026
According to the results reported on ClinicalTrials.gov, this trial (NCT04811092) enrolled 321 adults with pulmonary arterial hypertension (PAH) — a condition affecting blood pressure in the lungs. Around 161 people were assigned to receive sotatercept alongside their usual PAH medicines, and 160 received a placebo (a dummy treatment) alongside their usual PAH medicines. The trial's main goal was to measure how long it took before participants experienced a significant health setback, such as hospitalisation, a procedure, or death — referred to as "clinical worsening." The reported data shows...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT05339087 · results posted 21 January 2026
According to the results reported on ClinicalTrials.gov, this trial enrolled 35 people in total — 17 received riociguat and 18 received a placebo (a dummy treatment with no active ingredient). The trial ran for 24 weeks and was designed to measure changes in how blood flows through the lungs, as well as exercise capacity and breathing function. By the end of the study, 16 participants in each group had completed the trial. The reported data shows that the main thing being measured was a value called Pulmonary Vascular Resistance (PVR) — essentially the resistance the heart faces when pumping...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT05764265 · results posted 26 December 2025
According to the results reported on ClinicalTrials.gov, this trial (NCT05764265) enrolled 31 people in total — 23 who received the active treatment (LTP001 6 mg) and 8 who received a placebo (an inactive look-alike). The trial was studying LTP001 as a potential treatment for pulmonary hypertension (a condition involving high blood pressure in the arteries of the lungs). It was designed to run for up to 52 weeks, but the study was terminated early, meaning no participant completed the full planned duration. The main thing being measured was how many participants experienced adverse events (unw...
-
NCT05564637 · results posted 3 December 2025
According to the results reported on ClinicalTrials.gov, this trial enrolled 24 people in total — 23 patients with a condition called PAH-ILD (a combination of pulmonary arterial hypertension and interstitial lung disease) and 1 healthy volunteer for comparison. Of those, 22 PAH-ILD patients and the 1 healthy volunteer completed the study. The trial was measuring how the heart and lungs perform during exercise, using a procedure called right heart catheterisation (a thin tube inserted into the heart to take direct measurements). The main thing being measured was "cardiac output reserve" — esse...
-
NCT03648385 · results posted 5 November 2025
According to the results reported on ClinicalTrials.gov, this trial (NCT03648385) enrolled 26 adults in total — 14 in one group and 12 in the other — and all 26 completed the study with no dropouts. It was a crossover design, meaning one group took DHEA (a hormone supplement) first and then switched to a placebo, while the other group did the reverse. The trial was measuring how the right side of the heart — the chamber that pumps blood to the lungs — functioned over time, using specialised heart MRI scans. The key things being tracked were how well the right heart muscle stretches and squeeze...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT02932410 · results posted 12 September 2025
According to the results reported on ClinicalTrials.gov, this trial (NCT02932410) enrolled 165 children and young people with pulmonary arterial hypertension (PAH) — a condition affecting blood pressure in the lungs. Participants were divided into four groups based on age and treatment: those aged 2 years and over who received macitentan (73 participants), those aged 2 and over who received standard of care (75 participants), those under 2 years old who received macitentan (9 participants), and a separate group of 8 teenagers aged 12 to under 18 from China who also received macitentan. The tri...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT04896008 · results posted 22 August 2025
According to the results reported on ClinicalTrials.gov, this trial (NCT04896008) enrolled 172 people with pulmonary arterial hypertension (PAH — a condition involving high blood pressure in the arteries of the lungs), with 86 assigned to receive sotatercept and 86 assigned to receive a placebo (an inactive treatment used for comparison). The trial's main goal was to measure how long it took before a participant experienced a serious illness-related event or death — specifically, death from any cause, a lung transplant, or a hospital stay of at least 24 hours due to worsening PAH. By the end o...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT03122730 · results posted 31 July 2025
According to the results reported on ClinicalTrials.gov, this trial investigated a medicine called VentaProst in people with a condition affecting blood pressure in the lungs (pulmonary hypertension). The trial had two parts. In Part 1, nine participants were enrolled and seven completed that stage. In Part 2, eight participants started and all eight completed. The trial was measuring what dose of VentaProst would produce a similar body response (changes in blood flow and pressure readings) to an existing standard treatment called epoprostenol. The reported data shows that in Part 1, a VentaP...
-
NCT05135000 · results posted 15 May 2025
According to the results reported on ClinicalTrials.gov, this trial (NCT05135000) enrolled 47 people in total — 35 received a treatment called LTP001 and 12 received a placebo (a dummy treatment with no active ingredient). The trial was studying people with pulmonary hypertension, a condition involving high blood pressure in the lungs. The main thing researchers were measuring was a change in something called pulmonary vascular resistance (PVR) — essentially, how much resistance there is to blood flowing through the lungs — after 25 weeks. A number of other measurements were also taken, includ...
-
NCT04271475 · results posted 22 April 2025
According to the results reported on ClinicalTrials.gov, this trial (NCT04271475) enrolled 127 people in its main double-blind phase — 64 received macitentan and 63 received a placebo (a dummy treatment). The trial was examining whether macitentan made a difference for people with a specific lung condition, using several measurements including how far participants could walk in six minutes, how long it took for their condition to worsen, how they rated their symptoms, and their overall quality of life. A small number of participants (7 in total) continued into an open-label phase where everyon...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT04732221 · results posted 21 February 2025
According to the results reported on ClinicalTrials.gov, this trial tested an inhaled investigational medicine called MK-5475 in people with pulmonary arterial hypertension (PAH) — a condition where the blood pressure in the arteries supplying the lungs is abnormally high. The trial had two phases: a base period, where 168 participants were randomly assigned to receive either a placebo (dummy treatment) or one of three doses of MK-5475 (32, 100, or 380 micrograms), and an extension period, where a further 135 participants received one of the three doses. The trial was measuring, among other th...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT05337943 · results posted 27 January 2025
According to the results reported on ClinicalTrials.gov, this trial enrolled a very small number of participants — just 6 people in total. They were divided across three groups: one person received Cognitive Behavioural Therapy for Insomnia (CBT-I, a structured talking-based approach to sleep problems), three people received Bright Light Therapy (exposure to a specially designed light source), and two people received Standard Care. The trial was measuring whether participants stayed in the study and completed all of the required procedures — this is called a "retention rate," and is often used...
-
NCT03576885 · results posted 15 January 2025
According to the results reported on ClinicalTrials.gov, this trial (NCT03576885) enrolled 32 participants in total — 16 in the active treatment group and 16 in the placebo group. A third "control group" was listed but had no participants. All 32 participants who started the study completed it. The trial was measuring outcomes in what appears to be a newborn or infant population, looking at three main things: death, a lung condition called bronchopulmonary dysplasia (BPD — a breathing problem that can develop in premature babies, identified by the need for breathing support or extra oxygen), a...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT03451630 · results posted 9 December 2024
According to the results reported on ClinicalTrials.gov, this trial enrolled 1,400 people across three groups: a "High-Touch" group (562 people, meaning more personal, face-to-face support after leaving hospital), a "High-Tech" group (552 people, meaning technology-based support), and an "Optimal Discharge Planning" group (286 people, receiving a structured planning approach). The trial was measuring how well each approach supported people after a hospital stay, looking at things like how confident people felt managing their own health, their general health status, their physical function, qua...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT02587325 · results posted 25 November 2024
According to the results reported on ClinicalTrials.gov, this was a Phase 1 dose-finding trial testing a drug called nab-sirolimus in people with a serious lung condition affecting blood pressure in the lungs (pulmonary arterial hypertension). A total of 15 people took part across five dose groups (cohorts), with 3–4 people in most groups and 1 in the smallest group. The trial had two parts: a main 16-week treatment period, and an optional 32-week extension. The main goal was to find out how many participants in each dose group experienced a "dose-limiting toxicity" — meaning a serious side ef...
-
NCT03950739 · results posted 1 November 2024
According to the results reported on ClinicalTrials.gov, this trial enrolled 51 people who had been using an inhaled medicine called Tyvaso (inhaled treprostinil) and then switched them to a different device for delivering the same medicine, called TreT. The trial was measuring three main things: how far participants could walk in six minutes, how satisfied they were with the new device compared to the old one, and how they rated their own pulmonary arterial hypertension (PAH — a condition affecting blood pressure in the lungs) symptoms and their impact on daily life. Of the 51 who started the...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT03617458 · results posted 16 October 2024
According to the results reported on ClinicalTrials.gov, this trial (NCT03617458) enrolled 73 people across four groups: one group received metformin (a medicine) combined with an mHealth intervention (a digital/mobile health support tool); a second received a placebo (a dummy treatment) combined with usual care; a third received metformin with usual care; and a fourth received a placebo with the mHealth intervention. The trial ran for 12 weeks and was primarily measuring two things: how far participants could walk in six minutes, and whether their World Health Organization (WHO) Functional Cl...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT05557942 · results posted 10 October 2024
According to the results reported on ClinicalTrials.gov, this trial (NCT05557942) involved 186 participants across six groups. Some participants had previously received a placebo and then switched ("crossed over") to one of three doses of a medicine called AV-101 (10 mg, 35 mg, or 70 mg), while others continued on AV-101 at those same doses throughout. The trial was measuring the number of participants who experienced what are called "treatment-emergent adverse events" — that is, any unexpected medical occurrence that happened after receiving the study drug, regardless of whether it was though...
-
NCT03015402 · results posted 7 June 2024
According to the results reported on ClinicalTrials.gov, this trial looked at a treatment called oral nitrite in people with a condition affecting blood pressure in the lungs (pulmonary hypertension related to heart failure). It was a "crossover" trial, meaning participants took both the nitrite treatment and a dummy treatment (placebo) at different times, in random order, with a two-week break in between. A total of 24 people were enrolled across two groups — 13 started with nitrite first, and 11 started with placebo first. By the end of the study, 21 people completed both treatment periods....
-
NCT03542812 · results posted 2 May 2024
According to the results reported on ClinicalTrials.gov, this trial (NCT03542812) enrolled 16 premature infants considered at high risk of developing a lung and blood pressure condition called BPD-PH. Participants were split into two groups: 10 infants in a "single-dose" group (who received one dose of an oral supplement called L-citrulline) and 6 infants in a "steady-state" group (who received doses every 6 hours over 72 hours, for 12 doses total). All 16 participants completed the trial. The trial was measuring how L-citrulline levels in the blood changed over time after dosing, whether a ta...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT04370873 · results posted 26 April 2024
According to the results reported on ClinicalTrials.gov, this trial (NCT04370873) looked at an investigational inhaled medicine called MK-5475 in two separate parts. In Part 1, nine people took part over seven days — six received MK-5475 at a dose of 360 micrograms and three received a placebo (an inactive substance used for comparison). In Part 2, thirteen people took part over twenty-eight days — eight received MK-5475 at a slightly higher dose of 380 micrograms and five received a placebo. All participants in both parts completed their assigned dosing period. The trial was primarily measuri...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT03044314 · results posted 2 April 2024
According to the results reported on ClinicalTrials.gov, this trial enrolled 27 people, all of whom received both inhaled nitric oxide and a drug called iloprost. These are medicines that cause blood vessels to relax, and the trial was measuring how blood pressure in the lungs (pulmonary artery pressure) changed after each one was given. Twenty-three participants completed the trial, and four did not finish. The reported data shows that, on average, lung blood pressure dropped by about 10.7% after inhaled nitric oxide was given, and by about 13.3% after iloprost was given — these are the figu...
-
NCT02261883 · results posted 5 March 2024
According to the results reported on ClinicalTrials.gov, this trial (NCT02261883) enrolled 42 newborns or young patients in total — 21 received an intravenous medication called Remodulin (treprostinil), and 21 received a placebo (an inactive treatment). The trial was measuring "clinical worsening," which was defined as any one of three events: death, the need for a life-support machine called ECMO, or the need to start an additional lung-vessel medication. Several secondary measurements were also tracked, including how well the lungs were moving oxygen into the blood (using measures called the...
-
NCT05039086 · results posted 20 February 2024
According to the results reported on ClinicalTrials.gov, this study looked at Medicare health records in the United States (from January 2008 to December 2018) to compare two groups of people who had been prescribed different types of medication for pulmonary arterial hypertension (a condition affecting blood pressure in the lungs): one group took medicines called PDE5 inhibitors (9,968 people at the start) and the other took medicines called endothelin receptor antagonists (3,053 people at the start). The study's main question was whether there was any difference between the two groups in how...
-
NCT02587936 · results posted 20 December 2023
According to the results reported on ClinicalTrials.gov, this trial enrolled 9,730 people in the Intervention group and 8,538 people in the Usual Care group — a total of over 18,000 participants. The trial was looking at people who had three conditions at the same time: chronic kidney disease, diabetes, and high blood pressure. It was measuring whether an intervention (compared to standard care) was associated with differences in unplanned hospital admissions over 12 months, as well as related events such as readmissions within 30 days. The reported data shows that, for the primary measure —...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT03904693 · results posted 13 November 2023
According to the results reported on ClinicalTrials.gov, this trial (NCT03904693) enrolled 187 participants across three groups during the main double-blind phase (lasting 16 weeks): 35 people received macitentan monotherapy (a single medicine), 44 received tadalafil monotherapy (a single medicine), and 108 received a fixed-dose combination (FDC) tablet containing both medicines together. Participants had pulmonary arterial hypertension (a condition involving high blood pressure in the arteries of the lungs) and were divided based on what treatments, if any, they had previously taken. After th...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
See all 133 reported results for Pulmonary Hypertension
These are the results as reported to the registry, not medical advice. Verify independently with the trial site and discuss what they mean for you with your doctor.
What is coming
AI generated pipeline summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
According to NIH funding data, a very large amount of public research money has been directed toward Pulmonary Hypertension, which signals that this condition has attracted serious scientific attention at a global level. However, the direction of that funding has been falling year on year, meaning the field may be entering a more mature phase where basic questions have been answered, or that fundi...
See the full Pulmonary Hypertension page
Not medical advice. Voxsanity republishes public government health data in plain English. These figures describe research and registry activity, not the suitability of any treatment for any person. Trial status can change; always verify current status directly with the trial site and confirm Australian availability with your doctor.